Seqens Seqens

X
[{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Enters Collaborative Agreement with Regeneron","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Confo Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The agreement will leverage Confo’s expertise in addressing two GPCR targets for which functional antibodies are needed. Confo’s ConfoBody-based technology platform aims to overcome the limitations of drug discovery on GPCRs.

            Lead Product(s): Antibody Medicines

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY